Biotech Values

[DewDiligence]

Bayer reports (but ONXX issued this PR) positive phase-3 PFS data for Regorafenib in third-line GIST:

http://finance.yahoo.com/news/phase-3-data-regorafenib-met-041700269.html

Onyx Pharmaceuticals (ONXX) today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of progression-free survival (PFS) (HR=0.27, p<0.0001).

In keeping with this board’s new policy, I am deliberately not citing the median PFS values of the trial arms :- )